4576 Stock Overview A biotechnology company, focuses on discovery and development of various drugs. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
D. Western Therapeutics Institute, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for D. Western Therapeutics Institute Historical stock prices Current Share Price JP¥132.00 52 Week High JP¥254.00 52 Week Low JP¥60.00 Beta 0.30 1 Month Change -10.81% 3 Month Change 91.30% 1 Year Change 10.92% 3 Year Change -36.23% 5 Year Change -73.17% Change since IPO -66.58%
Recent News & Updates
Full year 2024 earnings released: JP¥36.73 loss per share (vs JP¥25.55 loss in FY 2023) Feb 11
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 25, 2025 Feb 10
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2024 Results on Feb 10, 2025 Dec 03
Health Check: How Prudently Does D. Western Therapeutics Institute (TSE:4576) Use Debt? Nov 28
D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Aug 27
Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023) Aug 14 See more updates
Full year 2024 earnings released: JP¥36.73 loss per share (vs JP¥25.55 loss in FY 2023) Feb 11
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 25, 2025 Feb 10
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2024 Results on Feb 10, 2025 Dec 03
Health Check: How Prudently Does D. Western Therapeutics Institute (TSE:4576) Use Debt? Nov 28
D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Aug 27
Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023) Aug 14
New major risk - Share price stability Aug 05
New minor risk - Shareholder dilution Jul 23
Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly? May 23
First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023) May 17
New minor risk - Shareholder dilution May 10
Insufficient new directors May 09
D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024 Feb 28
D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 Feb 14
Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022) Feb 11
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024 Feb 11
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024 Dec 13
New major risk - Revenue and earnings growth Nov 12
Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022) Nov 12
New minor risk - Share price stability Oct 03
D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023 Aug 27
Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022) Aug 12
D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jun 09
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 May 17
First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022) May 17
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023 Feb 15
Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021) Feb 15
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023 Feb 14
D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023 Dec 06
Insufficient new directors Nov 16
Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021) Nov 13
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 Nov 12
D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Aug 28
Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021) Aug 11 D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc. Jul 20
D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jun 02
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 May 14
Insufficient new directors Apr 27
D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022 Feb 27
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 Feb 15
D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022 Feb 12
D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021 Mar 03
D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Sep 12
D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm Aug 08
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm Jul 23 Shareholder Returns 4576 JP Biotechs JP Market 7D -5.0% 6.5% 0.8% 1Y 10.9% 17.9% 4.1%
See full shareholder returns
Return vs Industry: 4576 underperformed the JP Biotechs industry which returned 17.9% over the past year.
Return vs Market: 4576 exceeded the JP Market which returned 4.1% over the past year.
Price Volatility Is 4576's price volatile compared to industry and market? 4576 volatility 4576 Average Weekly Movement 24.8% Biotechs Industry Average Movement 8.7% Market Average Movement 3.5% 10% most volatile stocks in JP Market 7.5% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4576's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4576's weekly volatility has increased from 14% to 25% over the past year.
About the Company D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension.
Show more D. Western Therapeutics Institute, Inc. Fundamentals Summary How do D. Western Therapeutics Institute's earnings and revenue compare to its market cap? 4576 fundamental statistics Market cap JP¥5.49b Earnings (TTM ) -JP¥1.29b Revenue (TTM ) JP¥471.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4576 income statement (TTM ) Revenue JP¥471.58m Cost of Revenue JP¥46.84m Gross Profit JP¥424.74m Other Expenses JP¥1.72b Earnings -JP¥1.29b
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -31.00 Gross Margin 90.07% Net Profit Margin -273.61% Debt/Equity Ratio 108.7%
How did 4576 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/15 00:44 End of Day Share Price 2025/02/14 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources D. Western Therapeutics Institute, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
